非組織特異性堿性磷酸酶(ALPL)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Alkaline Phosphatase, Tissue-nonspecific (ALPL)
BALP; BSAP; HOPS; AP-TNAP; TNSALP; Bone Alkaline Phosphatase; Alkaline Phosphatase,Tissue-Nonspecific Isozyme; Alkaline Phosphatase, Liver/Bone/Kidney
- 編號(hào)CEB091Rb
- 物種Oryctolagus cuniculus (Rabbit,兔)相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)2h
- 檢測(cè)范圍1.23-100ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.47ng/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格48T96T96T*596T*1096T*100
- 價(jià)格¥ 3032¥ 4332¥ 19494¥ 36822¥ 303240
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測(cè)非組織特異性堿性磷酸酶(ALPL),經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的非組織特異性堿性磷酸酶(ALPL)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 92-102 | 97 |
| EDTA plasma(n=5) | 84-91 | 87 |
| heparin plasma(n=5) | 97-105 | 102 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的非組織特異性堿性磷酸酶(ALPL),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中非組織特異性堿性磷酸酶(ALPL)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 96-104% | 91-98% | 80-89% | 94-102% |
| EDTA plasma(n=5) | 95-103% | 78-104% | 90-102% | 78-101% |
| heparin plasma(n=5) | 80-89% | 83-91% | 95-105% | 81-101% |
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品及樣本)50µL,
加入50µL檢測(cè)液A(臨用前配制);
37°C溫育1小時(shí)。
3. 洗板3次;
4. 加檢測(cè)溶液B100µL,37°C孵育30分鐘;
5. 洗板5次;
6. 加TMB底物90µL,37°C孵育10-20分鐘;
7. 加終止液50µL,立即450nm讀數(shù)。
實(shí)驗(yàn)原理
本試劑盒應(yīng)用競(jìng)爭(zhēng)抑制酶聯(lián)免疫分析法測(cè)定標(biāo)本中待測(cè)物質(zhì)水平。將非組織特異性堿性磷酸酶(ALPL)單克隆抗體包被微孔板,制成固相載體,往包被抗體的微孔中同時(shí)加入生物素標(biāo)記的抗原和待測(cè)抗原(標(biāo)準(zhǔn)品或樣本),待測(cè)抗原與生物素標(biāo)記抗原對(duì)特異性抗體進(jìn)行競(jìng)爭(zhēng)結(jié)合。溫育后經(jīng)洗滌去掉未結(jié)合物,然后加入HRP標(biāo)記的親和素,經(jīng)過(guò)溫育和徹底洗滌后加入底物TMB顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色,并在酸的作用下轉(zhuǎn)化成最終的黃色。待測(cè)標(biāo)本濃度越高,標(biāo)記抗原和抗體的結(jié)合就越受到抑制,顯色愈淺。顯色的深淺與酶量呈正相關(guān),而與樣品中待測(cè)物質(zhì)含量呈負(fù)相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值),計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種:Oryctolagus cuniculus (Rabbit,兔) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
| SEB091Rb | 非組織特異性堿性磷酸酶(ALPL)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| CEB091Rb | 非組織特異性堿性磷酸酶(ALPL)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB091Rb | 非組織特異性堿性磷酸酶(ALPL)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Journal of Materials Science: Materials in Medicine | Osteopenic bone cell response to strontium-substituted hydroxyapatite[SpringerLink: n8233337w171v451] |
| Osteoporosis International | Dextromethorphan inhibits osteoclast differentiation by suppressing RANKL-induced nuclear factor-κB activation[PubMed: 23400250] |
| Journal of Applied Toxicology | Chronic exposure to low concentrations of strontium 90 affects bone physiology but not the hematopoietic system in mice[Wiley: Source] |
| Acta Pharmacologica Sinica | The antidepressant bupropion exerts alleviating properties in an ovariectomized osteoporotic rat model[Pubmed:25544359] |
| Biomedical Materials | Enhanced differentiation of osteoblastic cells on novel chitosan/β-1, 3-glucan/bioceramic scaffolds for bone tissue regeneration[Pubmed:25586067] |
| Pharmacology | Effect of Mirtazapine on Rat Bone Tissue after Orchidectomy[PubMed: 25871861] |
| J Biomed Mater Res A. | New method for the fabrication of highly osteoconductive β-1,3-glucan/HA scaffold for bone tissue engineering: Structural, mechanical, and biological characterization.[Pubmed:27239050] |
| J Bone Miner Metab | MiR-142-5p promotes bone repair by maintaining osteoblast activity[Pubmed:27085967] |
| Journal of Biomedical Materials Research | New method for the fabrication of highly osteoconductive β‐1, 3‐glucan/HA scaffold for bone tissue engineering: Structural, mechanical, and biological …[doi:10.1002] |
| Journal of?Bone?and?Mineral?Metabolism | MiR?142?5p promotes bone repair by maintaining osteoblast activity[pubmed:27085967] |
| Scientific Reports | Hydrolysis of Extracellular Pyrophosphate increases in post-hemodialysis plasma[Pubmed:30038263] |
| International?Journal?of?Molecular?Sciences? | Suppression Effect of Astaxanthin on Osteoclast Formation In Vitro and Bone Loss In Vivo[Pubmed:29562730] |
| Pharmacology | Effects of Amlodipine on Bone Metabolism in Orchidectomised Spontaneously Hypertensive Rats[Pubmed:29898457] |
| Experimental and Therapeutic Medicine | Combination therapy with BMP?2 and psoralen enhances fracture healing in ovariectomized mice[10.3892:etm.2018.6353] |
| American Journal of Translational?Research | Long non-coding RNA SNHG7 promotes the fracture repair through negative modulation of miR-9[] |
| The effect of low temperature atmospheric nitrogen plasma on MC3T3-E1 preosteoblast proliferation and differentiation in vitro[] | |
| International Journal of Biomaterials | Bovine Hydroxyapatite-Based Bone Scaffold with Gentamicin Accelerates Vascularization and Remodeling of Bone Defect[34104195] |





